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ABSTRACT
Objective
The objective of this systematic review is to examine the efficacy of beta amyloid immunization
in reducing amyloid plaques and preserving cognitive function in patients with Alzheimer’s
disease (AD).
Study Design
Review of three English language randomized, placebo-controlled, double-blind clinical trials
from 2005-2009.
Data Sources
Randomized, placebo-controlled, double-blind clinical trials comparing active immunization
with aggregated human β-amyloid AN1792 and QS-21 (an adjuvant) to placebo were found
using the Cochrane Database of Randomized Controlled Trials, the Cochrane Database of
Systematic Reviews, and Ovid MEDLINE.
Outcome(s) Measured
Cognitive function compared to baseline as measured using three cognitive tests: the
Alzheimer’s Disease Assessment Scale Cognitive Sub-scale (ADAS-Cog), which is measured on
a scale from 0-70 in which a higher score indicates greater impairment; the Folstein Mini-Mental
State Examination (MMSE), which is measured on a scale from 0-30 and in which a lower score
indicates greater impairment; and a Neuropsychological Test Battery (NTB) that consisted of
nine components with varying scores.
Results
The Bayer trial (phase Ib) showed a positive antibody response to AN1792, but the ADAS-Cogs
scores increased and MMSE scores decreased in both the active and control groups during the
study, indicating a decline in cognition. The Bayer trial did not utilize the NTB. The Gilman
trial (phase IIa) showed no significant difference in cognitive function between the active and
control groups using the ADAS-Cog and MMSE, but the NTB showed cognitive improvement
compared with the placebo group and a small improvement from baseline when measured at
month 12. However, the Gilman trial ended prematurely after 6% of the patients (18/300)
developed aseptic meningoencephalitis. The cohort study of the phase IIa trial (Vellas) was
conducted 4.6 years after immunization with AN1792, and showed no significant change from
baseline or differences between antibody responders and placebo group using the ADAS-Cog,
MMSE, and NTB scores.
Conclusions
This therapy does not appear to maintain nor enhance long-term cognitive function in patients
with AD.
Key Words
Alzheimer’s disease, amyloid-beta plaque, AN1792, vaccine, immunization, immunotherapy

INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of dementia worldwide. It is an
irreversible, progressive brain disease that affects memory, cognition, personality, and ultimately
the ability to perform activities of daily living (ADLs). The typical age of onset is after age 60
and the disease progresses over several years with a mean survival of 8-10 years after the initial
onset of symptoms1.
The increasing aging population confers significant relevance to AD for patients and
primary care providers, including Physician Assistants. In the US, AD currently affects about 5.3
million Americans and is the 6th leading cause of death2. The prevalence of AD is about 13% in
people 65 and older and 44% in people 85 years and older3. By 2050, it is estimated that 1 out of
every 85 persons in the world will be affected by AD2. Estimated annual spending in the US on
care, treatment, and lost productivity of those with AD and caregivers is $172 billion3, while
worldwide estimated annual spending is about $605 billion4.
There is currently no cure for AD; the existing treatments focus on symptom relief and
retarding the progression of the disease. It is known that AD is characterized by the deposition of
β-amyloid plaques, an accumulation of neurofibrillary tangles, and neuronal degeneration and
atrophy of the cerebral cortex leading to a subsequent, progressive loss of cognitive function.
There is an “amyloid hypothesis” which states that an imbalance in the production (with
subsequent accumulation and aggregation) of beta-amyloid plaques in the brain is neurotoxic and
is the main cause of neuronal degeneration and dysfunction5. The etiology of the amyloid
plaques is unknown; only potential risk factors have been identified (i.e., presence of the
APOE 4 allele, DM type 2, cardiovascular factors, sedentary lifestyle, dietary cholesterol, head
injury, female gender, viral/bacterial infection, Down’s Syndrome, obstructive sleep apnea).
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There are no reliable antemortem diagnostic tests available as AD can only be truly confirmed on
autopsy, and to date there are no measures proven to prevent AD.
The US Food and Drug Administration has approved five drugs that have been shown to
temporarily slow the progression of the disease in about half of the population taking the drugs3.
For mild to moderate AD there are the acetylcholinesterase inhibitors donezepil (Aricept®),
galantamine (Razadyne®), rivastigmine (Exelon®), and tacrine (Cognex®). For moderate to severe
AD there is an adjunct drug memantine (Namenda®) which is an N-methyl-D-aspartate receptor
blocker. Other treatments include behavioral management such as maintaining familiar
surroundings, daily moderate cognitive stimulation, and daily routines such as scheduled feeding,
toileting, etc.
Current pharmacological treatments for AD provide only modest symptomatic relief and
questionable prevention of disease progression. Because amyloid-beta (Aβ) peptides that form
the β-amyloid plaques appear to play a fundamental role in the development of AD, clearance of
Aβ from the brain is believed to be an important therapeutic strategy for the prevention and
treatment of AD. Immunotherapy targeting Aβ has been effective in reducing plaque burden and
improving cognition in transgenic mouse models of AD6. The following randomized, placebocontrolled, double-blind clinical trials and one cohort study to be examined have compared
active immunization to placebo for changes in cognition, whole-brain volume, safety, and
tolerability.
OBJECTIVE
The objective of this systematic review is to determine whether or not beta amyloid
immunization preserves cognitive function in patients with Alzheimer’s disease.

Sasin, β-Amyloid Immunization in AD 3

METHODS
The following studies were searched for using the Cochrane Database of Randomized
Controlled Trials, the Cochrane Database of Systematic Reviews, and Ovid MEDLINE. All of
the trials were published in the English language by peer-reviewed journals. Key words used in
searches were: Alzheimer’s disease, amyloid-beta plaque, AN1792, vaccine, immunization, and
immunotherapy. The inclusion criteria consisted of: 1) the studies were randomized, placebocontrolled, double-blind clinical trials, 2) patients with Alzheimer’s disease ≤ 85 years, 3) the
intervention used was immunization with aggregated human β-amyloid AN1792 + QS-21 (an
adjuvant) +/- 0.4% polysorbate-80 (an emulsifier) and matched placebo, 4) the outcomes
measured dealt with patient-oriented evidence that matters (POEMS), and 5) the trials had not
already been used in a systematic review or meta-analysis. The exclusion criteria were studies
that dealt with disease-oriented evidence (DOEs) and studies that had already been published in
systematic reviews or meta-analyses. Under these criteria, the following three studies were
chosen to be analyzed: 1) RCT-Phase 1b (Bayer et al) comparing AN1792 + QS-21 with
matched placebo (QS-21) and matched placebo (QS-21 + 0.4% polysorbate-80), 2) RCT-Phase
2a (Gilman et al) comparing AN1792 + QS-21 with matched placebo (QS-21), and 3) a cohort
study (Vellas et al) of the Bayer et al trial after 4.6 years. Table 1 includes the demographics and
characteristics of the included studies. The statistics used in the studies were p-values with
confidence intervals (CIs), and Analysis of Covariance (ANCOVA).
OUTCOMES MEASURED
The three studies used several means to measure outcome, but for the scope of this
analysis the outcomes measured was cognitive function as compared to baseline and the placebo
group. The cognitive function tests used were the Alzheimer’s Disease Assessment Scale
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Table 1 – Demographics and Characteristics of Included Studies
Study
Bayer et
al, 2005

Type
RCT
(doubleblind,
placebocontrolled)
phase 1b

#Pts
80

Age
≤ 85
yrs

Inclusion Criteria
•Aged ≤ 85 years who lived
with their caregivers and met
the criteria for diagnosis of
probable AD as defined by the
NINDS-ADRDA.
•MMSE score of 14-26.
•Rosen-Modified Hachinski
Ischemic score of ≤ 4.

Exclusion Criteria
None stated

W/D
24

Gilman
et al,
2005

RCT
(doubleblind,
placebocontrolled)
phase 2a

372

5085
yrs

•Aged 50-85 years who met
the criteria for diagnosis of
probable AD as defined by the
NINDS-ADRDA.
•MRI brain scan supporting
the clinical diagnosis of AD.
•MMSE score of 15-26.
•Rosen-Modified Hachinski
Ischemic score of ≤ 4.

96

Vellas et
al, 2009

Cohort
study of
Gilman after
4.6 yrs

25

5085
yrs

•Participation in the phase 2a
study.
•Positive antibody responders
(anti-beta amyloid titers ≥ 1:
2,200)

•Pre-existing diagnosis of a clinically
significant neurologic disease other than
AD that might affect cognition, major
psychiatric disorder, systemic illness, or
symptoms that could affect the subject’s
ability to complete the study.
•Hamilton Psychiatric Rating Scale for
Depression score of > 12.
• Prior use of an anticonvulsant,
antiparkinsonian, anticoagulant, narcotic,
or immunosuppressive medication with
the potential to affect cognition (unless
maintained on a stable low to moderate
dose regime for at least 3 months prior to
baseline).
• Prior use of medications for cognitive
enhancement other than a stable dosing
regimen of an acetylcholinesterase
inhibitor for ≥ 6 months.
•Same as Gilman study

0

Interventions
Aggregated
human beta
amyloid
AN1792 (50 or
225 μg IM) +
QS-21 (50 or
100 μg IM +/0.4%
polysorbate-80)
AN1792 (225
μg IM) + QS21 (50 μg IM)

Prior
immunization
with AN1792
(225 μg IM) +
QS-21(50 μg
IM)
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Cognitive Sub-scale (ADAS-Cog), the Folstein Mini-Mental State Examination (MMSE), and a
Neuropsychological Test Battery (NTB) consisting of nine unique components.
Bayer et al used 64 active and 16 control patients who were given either AN1792 50mcg
+ QS-21 50mcg, AN1792 50mcg + QS-21 100mcg, AN1792 225mcg + QS-21 50mcg, AN1792
225mcg + QS-21 100mcg, QS-21 50mcg, or QS-21 100 mcg7. Injections were given on day 0,
weeks 4, 12, and 24, and optional injections at weeks 36, 48, 60, and 72. During the extension
phase both the active and control immunizations included 0.4% polysorbate-80 to improve
product stability by preventing AN1792 from precipitating out of solution. ADAS-Cog and
MMSE were assessed by blinded raters at baseline, weeks 32, 64, 84, and a final visit consisting
of data from each patient’s last observation carried forward.
Gilman et al used 300 active patients who were given AN1792 225mcg + QS-21 50mcg
+ 0.4% polysorbate-80 and 74 control patients who were given saline injections at day 0, months
1, 3, 6, 9, and 128. The study was discontinued after 6% of the patients developed aseptic
meningoencephalitis. The patients only received between 1-3 injections and were enrolled in a 9
months safety follow-up program. ADAS-Cog, MMSE, and NTB tests were performed by
blinded raters at baseline, month 6, and month 12.
Vellas et al is a cohort study of the Gilman phase IIa trial, which analyzed 129 patients
given AN1792 and 30 who were given placebo9. ADAS-Cog, MMSE, and NTB tests were
performed by blinded raters during a clinic or home visit.
RESULTS
Table 2 shows the results of ADAS-Cog and MMSE testing during the Bayer et al trial.
The ADAS-Cog test has been the standard primary outcome measure of cognition for AD since
1984, and a score ≥ 18 indicates greater cognitive impairment10. Using the Folstein MMSE, the
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highest score possible is 30. A score of 21-24 indicates mild cognitive impairment, 10-20 is
moderate, and ≤ 9 is considered severe cognitive impairment11. The patients included in the
study all were considered to have moderate cognitive impairment. The ADAS-Cog scores show a
progressive incline in both active and control groups, indicating a decline in cognition and
therefore no significant efficacy of the immunization. Similarly there was a progressive decline
in MMSE, also indicating a decline in cognition. The data was analyzed using ANCOVA with
the baseline value as the covariate and treatment and center as the main effects, reflecting the
same decline in cognition.
Table 2 - Effects of AN1792 + QS-21 or QS-21 Alone on ADAS-Cog and MMSE
Parameter

Baseline
Week 32
Week 64
Week 84
Observed
Mean (SD)
Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog)
QS-21 only
24.06 (8.71)
27.50 (11.78) 23.17 (10.95) 27.70 (11.23)
n=16
n=14
n=12
n=10
AN1792 + QS-21

22.59 (10.59) 24.61 (11.60)
n=64
n=57
Mini-Mental State Examination (MMSE)
QS-21 only
19.75 (4.28)
18.64 (5.17)
n=16
n=14
AN1792 + QS-21 20.92 (3.38)
18.81 (5.00)
n=64
n=57

Final visit

28.27 (11.91)
n=15

23.69 (9.43)
n=48

26.75 (11.29)
n=40

27.02 (12.63)
n=62

16.92 (6.68)
n=13
19.04 (5.37)
n=49

17.17 (6.63)
n=12
17.25 (6.35)
n=44

17.50 (6.19)
n=14
17.25 (6.97)
n=57

Table 3 shows the results of ADAS-Cog, MMSE, and NTB testing during the Gilman et
al trial. The authors only included patients in the active group who were positive antibody
responders (19.7%) compared to placebo. There was no difference between the treatment group
and placebo using the ADAS-Cog and MMSE; both groups showed a negative mean change
from baseline indicating worsening cognitive function. The high p scores for the ADAS-Cog and
MMSE indicate no statistical significance between responder and placebo groups. Raw scores on
the NTB were converted to z-scores and averaged, which was then analyzed using ANCOVA
with change from baseline z-score as the response, the baseline value as the covariate, and the
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treatment, MMSE stratum at baseline, and geographic location as independent variables. In the
NTB analysis, the antibody responders showed a statistically significant lesser cognitive decline.
Table 3 – Effects of AN1792 (QS-21) or Placebo on ADAS-Cog, MMSE, and NTB
Parameter

Baseline
Month 12
Observed mean
Observed mean change
Difference in adjusted
(SD)
from baseline (SD)
mean (95% CI)
Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog)
Placebo
23.9 (9.9); n=65
-2.7 (6.5); n=53
-0.7 (-3/5, 2.2)
Responder 21.7 (9.6); n=55
-3.8 (7.8); n=44
Mini-Mental State Examination (MMSE)
Placebo
20.3 (3.6); n=65
-1.8 (3.7); n=51
Responder

20.7 (3.3); n=55

0.11 (0.61); n=55

0.641

-0.3 (-1.8, 1.1)

0.678

-0.23 (-0.41, -0.04)

0.020

-1.5 (3.2); n=42

Neuropsychological Test Battery (NTB)
Placebo
0.08 (0.77); n=64 -0.20 (0.45); n=48
Responder

p value

0.03 (0.37); n=36

Table 4 shows the results from the Vellas et al cohort study. The ADAS-Cog and MMSE
tests showed no significant differences between antibody responders and placebo. The NTB tests
were analyzed using an ANCOVA model with change from the Gilman study baseline NTB
score as the response and the Gilman study baseline NTB as the covariate. NTB scores also
showed diminished cognitive function.
Table 4 – Effects of AN1792 (QS-21) or Placebo on ADAS-Cog, MMSE, and NTB in
Antibody Responders and Placebo Group 4.6 Years Later
Parameter

Baseline
4.6 Years After Last Immunization
Observed mean (SD)
Observed mean change
P value
from Gilman et al
from baseline (SD)
Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog)
Placebo
23.9 (9.9); n=65
14.4 (14.2); n=11
0.616
Responder 21.7 (9.6); n=55
14.3 (14.0); n=16
Mini-Mental State Examination (MMSE)
Placebo
20.3 (3.6); n=65
-8.3 (5.8); n=18
Responder

20.7 (3.3); n=55

-8.0 (7.8); n=20

Neuropsychological Test Battery (NTB)
Placebo
0.08 (0.77); n=64
-0.751 (0.560); n=10
Responder

0.11 (0.61); n=55

0.719

-0.597 (0.626); n=13

0.440
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Table 5 shows the most common adverse events (AEs) reported in two of the trials. In
Bayer et al, the most common AEs were accidental injury (38.8%), infection (31.3%), and
confusion (31.3%); the majority of the AEs were considered mild to moderate7. Ten patients
prematurely withdrew from the study due to AEs and five patients died during the study period
but none of the deaths were considered to be directly related to the study. There were no safety
concerns at the end of this trial to prevent the commencement of a larger phase II trial. In Gilman
et al, the most common AEs were accidental injury (15.3% placebo, 13.7% active), infection
(12.5% placebo, 19.0% active), and headache (9.7% placebo, 17.3% active) 8. Eighteen of the
300 active patients (6%) developed encephalitis. Thirteen of them were antibody responders, and
all 18 were still alive one year after the onset of symptoms12. Seventy-seven of the 300 active
patients and 19/72 placebo patients withdrew prematurely due to AEs. Seven patients died during
the follow-up study period, and one antibody non-responder’s death was considered to be related
to the treatment. Vellas et al collected data of serious adverse events (SAEs) that had occurred
since the end of the Gilman et al study, but did not report specific SAES, only overall incidence.
The occurrence of SAEs in the placebo group was 33.3% versus 40.0% in the antibody responder
group; no SAEs were considered to be related to treatment and no new cases of encephalitis were
observed9.
Table 5 – Profile of Adverse Events
Bayer et al
N (%)
Placebo
AN1792

Gilman et al
N (%)
Placebo
AN1792

Accidental injury

6 (37,5)

25 (39.1)

11 (15.3)

41 (13.7)

Confusion

5 (31.3)

20 (31.3)

6 (8.3)

35 (11.7)

Infection

5 (31.3)

20 (31.3)

9 (12.5)

57 (19.0)

Headache

3 (18.8)

7 (10.9)

7 (9.7)

52 (17.3)

Sasin, β-Amyloid Immunization in AD 9

The adverse event rates in the control group (control event rate, or CER) and the active or
experimental event rate (EER) are shown in Table 6. The experimental group shower higher
rates of adverse events in the Gilman et al and Vellas et al studies, but in the Bayer et al trial the
adverse event rate in the control group was 100%. The negative relative risk increase (RRI) in
the Bayer et al trial means an adverse event is less likely to occur in the experimental group than
in the control group. Specifically, an adverse event was 8.3% more likely to occur in the
experimental group as seen in the Gilman et al trial. The absolute risk increase (ARI) shows the
absolute difference in risk between the experimental and control groups. Numbers needed to
harm (NNH) is a measure of how many patients need to be exposed to a treatment to cause harm
in one patient. In the Gilman et al trial, for every 15 patients immunized with AN1792, one
patient experienced an adverse event. The negative NNH in the Bayer et al trial means that for
every 32 patients immunized, one less experienced an adverse event.
Table 6 – Analysis of Outcomes and Numbers Needed to Harm in Patients Immunized with
AN1792 (QS-21) vs. Placebo
Study
CER
EER
RRI
ARI
NNH
Bayer et al

100.0%

96.9%

-3.1%

-3.1%

-32

Gilman et al

81.9%

88.7%

8.3%

6.8%

15

Vellas et al

33.3%

40.0%

21.0%

6.7%

5

DISCUSSION
The Bayer et al trial did not show any improvement in cognitive function or a slowing of
the progression of AD, and demonstrated a few shortcomings. Out of all the patients who were
actively treated, about 53.1% had a positive antibody titer during the study7. It is difficult to
assess the efficacy of an immunization in which only half of the patients mount an immune
response. When the ADAS-Cog and MMSE were assessed, the final visit utilized data from each
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patient’s last observation carried forward (LOCF). This method of analysis is based on
assumption and may bias the estimate of treatment efficacy13.
In the Gilman et al trial, even fewer active group patients mounted an antibody response
(20%), although the trial ended prematurely after 1-3 injections8. A supplement from Bayer et al
to the Gilman et al trial was the addition of 0.4% polysorbate-80 to the active group injection. It
has been suggested that this may have been responsible for the meningoencephalitis by creating
an inflammatory T cell response, rather than the formation of antibodies14.
A major limitation to the Vellas et al trial was the lack of patients able to participate in
the study almost five years later. The original trial (Gilman et al) featured 300 active patients,
and 60 of those were antibody responders. Vellas et al was only able to procure 25 of those
responders. The Gilman et al trial also featured 74 placebo patients, while Vellas et al included
only 30 placebo patients. The placebo group may also been biased as the patients who were still
able to perform cognitive function tests would be inherently less impaired than their placebo
counterparts who were already too demented to participate. In addition, that the majority of all
participants in this study were currently taking acetylcholinesterase inhibitors or memantine,
which may have also been a confounding factor.
Finally, among each of the trials examined, many of the placebo group patients
experienced a significant amount of AEs. In Bayer et al, some AEs occurred twice as often in the
negative antibody responders, and therefore may have been associated with the progression of
AD or working with an aging population for an extended period of time.
CONCLUSION
It appears that active immunization with beta amyloid is ineffective at preserving the rate
of cognitive decline in patients with Alzheimer’s disease. Although the Gilman et al trial found
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that the NTB analysis showed a statistically significant lesser cognitive decline in the antibody
responders than the placebo group, Vellas et al showed that 4.6 years later there was no
significant difference observed in change from baseline between antibody responders and
placebo patients.
The major flaw in the basic design of the study is the enormous difference in comparing
human genetics to transgenic mice. Mice have much less genetic variability. Their plaques are
composed of a different chemical composition which is more soluble and easier to remove. In the
future, new therapies should be tested extensively on species that are genetically closer to
humans.
The Vellas et al trial did demonstrate significantly less impairment in ADLs and
dependence on caregivers in the antibody responders, which was not discussed in this analysis
but could potentiate further support for immunotherapy research in patients with mild to
moderate AD. More current immunotherapy research is focusing on passive immunization, and
there are several trials underway at the moment. The most advanced is a phase III trial with
bapineuzumab, a humanized anti-amyloid beta monoclonal antibody, which as of December
2010 is still actively recruiting participants15.
The ability to control the immune system to clear amyloid beta plaques could be
promising in not only the treatment of AD but many other neurodegenerative diseases that also
are attributed to abnormal protein formation, such as Creutzfeldt–Jakob disease (CJD),
Huntington’s chorea, and Parkinson’s disease. Future research in immunotherapy could
potentially provide a breakthrough in disease-altering therapy for many diseases of aging, which
are increasing in prevalence as the world population continues to age.
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